Copyright
©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Surg. Oct 27, 2025; 17(10): 109107
Published online Oct 27, 2025. doi: 10.4240/wjgs.v17.i10.109107
Published online Oct 27, 2025. doi: 10.4240/wjgs.v17.i10.109107
Fibrolamellar hepatocellular carcinoma: Advances, challenges and opportunities in a rare malignancy
Leonardo Gomes da Fonseca, Department of Medical Oncology, Instituto do Câncer do Estado de São Paulo, University of São Paulo, São Paulo 01246-000, Brazil
Raphael L C Araujo, Department of Surgery, Universidade Federal de São Paulo, São Paulo 04024-002, Brazil
Raphael L C Araujo, Department of Surgery, Hepato-Pancreato-Biliary Service, Atrium Health Carolinas Medical Center, Charlotte, NC 28204, United States
Author contributions: Da Fonseca LG and Araujo RLC contributed to the study conception, data preparation, data interpretation, and critical writing.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Raphael L C Araujo, MD, PhD, Adjunct Professor, FACS, Department of Surgery, Universidade Federal de São Paulo, No. 715 Rua Napoleão de Barros, São Paulo 04024-002, Brazil. raphael.l.c.araujo@gmail.com
Received: April 30, 2025
Revised: May 26, 2025
Accepted: August 7, 2025
Published online: October 27, 2025
Processing time: 177 Days and 23.2 Hours
Revised: May 26, 2025
Accepted: August 7, 2025
Published online: October 27, 2025
Processing time: 177 Days and 23.2 Hours
Core Tip
Core Tip: Fibrolamellar hepatocarcinoma is a rare subtype of primary liver cancer characterized by unique histological, clinical, and molecular features. Although surgical resection remains the cornerstone of curative treatment, advances in molecular biology and identifying specific genetic alterations hold promise for developing targeted therapies, potentially improving outcomes for patients with this rare disease.